Filing Flows › Agios Pharmaceuticals (AGIO) › Q3 2025
Agios Pharmaceuticals (AGIO) Q3 2025 earnings results (third quarter 2025)
10-Q filed Oct 30, 2025
Agios Pharmaceuticals (AGIO) reported revenue of $12.9M for the third quarter 2025 (Q3 2025), +44% from a year earlier and +3% from the quarter before. Operating margin was -907.4%, net loss $103M (803.1% of revenue).
Agios Pharmaceuticals, Q3 2025: revenue $12.9M (+44% year over year), operating margin -907.4%, net loss $103M, operating cash flow −$88.2M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $12.9M | +3% | +44% |
| Operating profit | −$117M | — | — |
| Net earnings | −$103M | — | — |
| Operating cash flow | −$88.2M | — | — |
What changed
Revenue was $12.9M in Q3 2025, up 44% year over year and up 3% from the previous quarter.
Operating costs exceeded revenue by $116.9M, an operating margin of -907.4%. Total costs grew 16% against revenue growth of 44%. The fastest-growing cost line was Cost of revenue (+114%). The quarter ended with a net loss of $103.4M, narrower than the previous quarter's $112.0M loss.
Operating cash flow was −$88.2M. Non-cash charges added back $12.4M of share-based compensation. Capital expenditures of $1.6M exceeded it, leaving free cash flow of −$89.7M.
Questions
What was Agios Pharmaceuticals' revenue in the third quarter 2025?
Agios Pharmaceuticals (AGIO) reported revenue of $12.9M for the third quarter 2025 (Q3 2025), +44% from a year earlier and +3% from the quarter before.
Was Agios Pharmaceuticals profitable in the third quarter 2025?
Operating loss was $117M (-907.4% of revenue) and net loss $103M.